• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Acerus Announces Closing of US$5 Million Secured Term Loan

    Jocelyn Aspa
    Jul. 19, 2019 09:52AM PST
    Pharmaceutical Investing

    Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) has announced it has entered into a US$5 million subordinated secured term loan facility with First Generation Capital. As quoted in the press release: he Loan is subordinated to the existing US$9 million facility with SWK Funding LLC (“SWK”) and bears interest at a rate per annum equal to the three-month …

    Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) has announced it has entered into a US$5 million subordinated secured term loan facility with First Generation Capital.

    As quoted in the press release:

    he Loan is subordinated to the existing US$9 million facility with SWK Funding LLC (“SWK”) and bears interest at a rate per annum equal to the three-month London Inter-Bank Offered Rate (“LIBOR”), plus an applicable margin of 10.50%. Subject to the terms of the subordination and intercreditor agreement between First Generation and SWK, the Loan is repayable in full on December 31, 2020, is interest-only until maturity with regularly scheduled payments of interest to First Generation being permitted subject to certain conditions related to Acerus’ market capitalization and aggregate annual revenue, and can be prepaid in full or in part without penalty following repayment in full of indebtedness owing to SWK. The proceeds from the Loan will be used for ongoing general working capital. A copy of the promissory note covering the loan will be filed under the Company’s profile on SEDAR at www.sedar.com.

    Click here to read the full press release.

    pharmaceutical investingtsx:aspacerus pharmaceuticals
    The Conversation (0)

    Go Deeper

    AI Powered
    Asante Signs Definitive Agreements to Unlock Approximately $500M of Financing Proceeds

    Asante Signs Definitive Agreements to Unlock Approximately $500M of Financing Proceeds

    VIDEO Round-Up BBHIC 2019

    VIDEO Round-Up BBHIC 2019

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×